Sutent is a brand name of sunitinib, approved by the FDA in the following formulation(s):
SUTENT (sunitinib malate - capsule; oral)
Manufacturer: CPPI CV
Approval date: January 26, 2006
Strength(s): EQ 12.5MG BASE, EQ 25MG BASE, EQ 50MG BASE [RLD]
Manufacturer: CPPI CV
Approval date: March 31, 2009
Strength(s): EQ 37.5MG BASE
Has a generic version of Sutent been approved?
No. There is currently no therapeutically equivalent version of Sutent available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sutent. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pyrrole substituted 2-indolinone protein kinase inhibitors
Patent 6,573,293
Issued: June 3, 2003
Inventor(s): Peng Cho; Tang & Todd A.; Miller & Xiaoyuan; Li & Li; Sun & Chung Chen; Wei & Shahrzad; Shirazian & Congxin; Liang & Tomas; Vojkovsky & Asaad S.; Nematalla & Michael; Hawley
Assignee(s): Sugen, Inc.
Pharmacia & Upjohn Co.
The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Patent expiration dates:
- February 15, 2021✓✓✓
- February 15, 2021
Pyrrole substituted 2-indolinone protein kinase inhibitors
Patent 7,125,905
Issued: October 24, 2006
Inventor(s): Tang; Peng Cho & Miller; Todd A. & Li; Xiaoyuan & Sun; Li & Wei; Chung Chen & Shirazian; Shahrzad & Liang; Congxin & Vojkovsky; Tomas & Nematalla; Asaad S. & Hawley; Michael
Assignee(s): Agouron Pharmaceuticals, Inc.
The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Patent expiration dates:
- February 15, 2021✓✓
- February 15, 2021
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
Patent 7,211,600
Issued: May 1, 2007
Inventor(s): Lipson; Ken & McMahon; Gerald
Assignee(s): Sugen Inc.
The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.Patent expiration dates:
- December 22, 2020✓
- December 22, 2020
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- January 26, 2011 - NEW CHEMICAL ENTITY
- May 20, 2014 - TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
See also...
- Sutent Consumer Information (Wolters Kluwer)
- Sutent Consumer Information (Cerner Multum)
- Sutent Advanced Consumer Information (Micromedex)
- Sutent AHFS DI Monographs (ASHP)
- Sunitinib Consumer Information (Wolters Kluwer)
- Sunitinib Consumer Information (Cerner Multum)
- Sunitinib Advanced Consumer Information (Micromedex)
- Sunitinib malate Advanced Consumer Information (Micromedex)
- Sunitinib Malate AHFS DI Monographs (ASHP)
